Panbela Announces Acceptance of Abstract for Poster Presentation at American Society of Clinical Oncology Gastrointestinal Cancers Symposium

Rhea-AI Summary

Panbela Therapeutics (Nasdaq: PBLA) announced the acceptance of an abstract for a poster presentation of SBP-101 at the ASCO Gastrointestinal Cancers Symposium from January 20-22, 2022. The presentation will focus on the efficacy of SBP-101, a polyamine metabolic inhibitor, in combination with gemcitabine and nab-paclitaxel for first-line treatment of metastatic pancreatic ductal adenocarcinoma. The safety profile shows no exacerbation of common chemotherapy-related adverse events. Further evaluation in a randomized clinical trial is planned.

Positive

• SBP-101 shows potential efficacy as a first-line treatment for metastatic pancreatic cancer.
• The safety profile of SBP-101 indicates no exacerbation of chemotherapy-related adverse events.
• The upcoming presentation at ASCO may enhance visibility and credibility in the oncology community.

Negative

• None.

MINNEAPOLIS, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer today announced that an abstract for SBP-101, a proprietary polyamine analogue, has been accepted for poster presentation at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, which will be held January 20-22, 2022.

Details of the presentation are as follows:

Poster Presentation

• Title: Efficacy of SBP-101, a polyamine metabolic inhibitor, administered in combination with gemcitabine and nab-paclitaxel, as a first-line treatment for patients with metastatic pancreatic ductal adenocarcinoma.
  
  
• Session Name: Poster Session B: Pancreas, Small Bowel, and Hepatobiliary Tract
  
  

Additional meeting information can be found on the ASCO website https://meetings.asco.org/gi/.   The full abstract will be made available online via https://meetinglibrary.asco.org at 5:00 PM (EST) on January 18, 2022.

About SBP-101
SBP-101 is a proprietary polyamine analogue designed to induce polyamine metabolic inhibition (PMI) by exploiting an observed high affinity of the compound for pancreatic ductal adenocarcinoma and other tumors. The molecule has shown signals of tumor growth inhibition in clinical studies of US and Australian metastatic pancreatic cancer patients, suggesting potential complementary activity with an existing FDA-approved standard chemotherapy regimen. In data evaluated from clinical studies to date, SBP-101 has not shown exacerbation of bone marrow suppression and peripheral neuropathy, which can be chemotherapy-related adverse events. Serious visual adverse events have been evaluated and patients with a history of retinopathy or at risk of retinal detachment will be excluded from future SBP-101 studies. The safety data and PMI profile observed in the current Panbela sponsored clinical trial provides support for continued evaluation of SBP-101 in a randomized clinical trial. For more information, please visit https://clinicaltrials.gov/ct2/show/NCT03412799 .

About Panbela
Panbela Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing disruptive therapeutics for patients with urgent unmet medical needs. The company’s initial product candidate, SBP-101, is for the treatment of patients with metastatic pancreatic ductal adenocarcinoma, the most common type of pancreatic cancer. Panbela Therapeutics, Inc. is dedicated to treating patients with pancreatic cancer and exploring SBP-101’s potential for efficacy in combination with other agents in other cancer indications. Further information can be found at www.panbela.com. Panbela Therapeutics, Inc. common stock is listed on The Nasdaq Stock Market LLC under the symbol PBLA.

Cautionary Statement Regarding Forward-Looking Statements
This press release contains “forward-looking statements,” including within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “believe,” “expect,” “intend,” “may,” and “plan.” Examples of forward-looking statements include statements we make regarding our intention to continue to innovate and build our patent portfolio. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations, and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially and adversely from the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: (i) our ability to obtain additional funding to complete a randomized clinical trial; (ii) progress and success of our Phase 1 clinical trial; (iii) the impact of the current COVID-19 pandemic on our ability to complete monitoring and reporting in our current clinical trial and procure the active ingredient; (iv) our ability to demonstrate the safety and effectiveness of our SBP-101 product candidate (v) our ability to obtain regulatory approvals for our SBP-101 product candidate in the United States, the European Union or other international markets; (vi) the market acceptance and level of future sales of our SBP-101 product candidate; (vii) the cost and delays in product development that may result from changes in regulatory oversight applicable to our SBP-101 product candidate; (viii) the rate of progress in establishing reimbursement arrangements with third-party payors; (ix) the effect of competing technological and market developments; (x) the costs involved in filing and prosecuting patent applications and enforcing or defending patent claims; and (xi) such other factors as discussed in Part I, Item 1A under the caption “Risk Factors” in our most recent Annual Report on Form 10-K, any additional risks presented in our Quarterly Reports on Form 10-Q and our Current Reports on Form 8-K. Any forward-looking statement made by us in this press release is based on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement or reasons why actual results would differ from those anticipated in any such forward-looking statement, whether written or oral, whether as a result of new information, future developments or otherwise.

Contact Information:

Investors:
James Carbonara
Hayden IR
(646) 755-7412
james@haydenir.com

Media:
Tammy Groene
Panbela Therapeutics, Inc.
(952) 479-1196 ext. 170
IR@panbela.com

FAQ

What is the significance of the SBP-101 presentation at ASCO for PBLA?

The presentation highlights the potential efficacy and safety of SBP-101, which could attract investor interest and enhance the company's reputation in oncology.

When will the SBP-101 abstract be available to the public?

The full abstract will be accessible online on January 18, 2022, at 5:00 PM EST.

What type of cancer is SBP-101 targeting?

SBP-101 is being developed for the treatment of metastatic pancreatic ductal adenocarcinoma.

What is the purpose of the ASCO Gastrointestinal Cancers Symposium?

The symposium serves as a platform for sharing new research and advancements in the treatment of gastrointestinal cancers.

What are the next steps for SBP-101 after the ASCO presentation?

Following the presentation, Panbela intends to continue evaluating SBP-101 in a randomized clinical trial.